Lantern Pharma

Lantern Pharma collaborates with leading innovators in oncology to accelerate drug discovery and development using AI-powered insights from RADR platform, advancing precision and efficiency in cancer research.

Lantern develops its AI platform, RADR, to accelerate cancer therapy development and personalize treatments.

The page describes Lantern’s clinical trials using machine learning in oncology, including Phase 1 and Phase 2 studies.

Lantern aims to deliver cost-effective therapies quickly through AI-driven drug development.

Lantern Pharma is fostering a workplace culture that inspires biotech professionals, cancer research careers, and provides the tools and vision needed for long-term success.

Lantern seeks collaborations on targeted cancer therapies and biotech treatment pipelines.

Lantern Pharma is a clinical stage oncology company that leverages artificial intelligent, machine learning, and genomics to develop targeted cancer therapies.

Lantern collaborates with institutions, researchers, and companies to develop cancer therapies using machine learning in drug discovery.

Lantern Pharma actively manages a patent portfolio that includes over 90 issued patents and pending applications across 14 patent families.

Lantern Pharma’s biotech innovations and oncology drug-development processes are reflected in numerous research publications and conference posters.

Lantern explores partnerships in cancer drug development, clinical studies, and targeted therapy innovations.

Lantern Pharma is an oncology-focused clinical stage pharmaceutical company leveraging Artificial Intelligence, Genomics, and Machine Learning to transform the cost, pace, and timeline of drug discovery and development.

The page outlines Lantern’s policies for data collection, privacy, and protecting sensitive information.